Source: Moffitt Cancer Centre, June 2025
Patients with advanced stage 3 melanoma that has spread to the regional lymph nodes but not yet to distant organs appear to benefit from a novel combination of two drugs rather than just one as currently applied in standard practice, researchers found.
According to Ahmad Tarhini, MD, PhD, director of the cutaneous clinical and translational research team at Moffitt Cancer Center, a recent trial presented at the American Society of Clinical Oncology annual meeting found that the combination of the drugs vidutolimod and pembrolizumab administered before surgery stimulates the immune system to fight cancer while also shrinking the tumor.